BJazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy treatments.
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy treatments.
Consumer News and Business Channel
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗
